JAKAVI 5 mg/ml, oral solution bottle, 60 ml
Active ingredients: Ruxolitinib phosphate, Ruxolitinib
Commercialized according to BDPMDispensing in France: Prescription only
Oral solutionbottle, 60 mlorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- JAKAVI 5 mg/mL, solution buvable
- Pharmaceutical form
- solution buvable
- Route of administration
- orale
- Presentation description
- 1 flacon en verre jaune(brun) avec fermeture de sécurité enfant de 60 mL + 2 seringues pour administration orale + adaptateur pour flacon
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 14 Apr 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68379069CIP73030843CIP133400930308431Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PHOSPHATE DE RUXOLITINIBsolution | — | SA |
| RUXOLITINIBsolution | 5 mg · 1 mL de solution | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.